FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy

/PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has...

Related Keywords

Australia ,Japan ,United States ,United Kingdom ,Belgium ,Melbourne ,Victoria ,Canada ,Switzerland ,Australian ,American ,Kyahn Williamson ,Kevin Richardson ,Oliver Sartor ,Telix Pharmaceuticals ,Linkedin ,Drug Administration ,Tulane Cancer Center ,Australian Securities Exchange ,Novartis ,Prnewswire Telix Pharmaceuticals Limited ,Australian Therapeutic Goods Administration ,Corporate Communications ,Health Canada ,American Cancer Society ,Pharmaceuticals Limited ,United States Food ,New Drug Application ,Chief Executive Officer ,Telix Americas ,Medical Director ,Telix Pharmaceuticals Limited ,Emission Tomography ,Computed Tomography ,Cancer Society ,Key Statistics ,Prostate Cancer ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Fda Approval ,